Numeta G13e (Valine, Ornithine Hydrochloride, Alanine, Arginine, Cysteine, Histidine, Isoleucine, Leucine, Methio)

Numeta G13e is used in clinical nutrition to provide essential amino acids for patients with increased metabolic needs.

• Critical care: helps maintain nitrogen balance and supports protein synthesis in intensive care patients.
• Post‑operative recovery: aids tissue repair and wound healing after major surgery.
• Long‑term parenteral nutrition: supplies a balanced amino acid profile for patients dependent on intravenous nutrition.

• Numeta G13e delivers a balanced mixture of essential and non‑essential amino acids directly into the bloodstream, bypassing gastrointestinal absorption. The amino acids serve as substrates for protein synthesis, support gluconeogenesis, and contribute to nitrogen balance, thereby meeting the metabolic demands of patients receiving parenteral nutrition.

Numeta G13e may be associated with infusion‑related reactions and metabolic disturbances.

Common Side Effects

• Hyperglycaemia: elevated blood glucose levels during infusion.
• Electrolyte imbalance: changes in serum potassium or phosphate.
• Mild fever: low‑grade temperature rise during administration.
• Local irritation: redness or discomfort at the infusion site.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergic response requiring immediate medical intervention.
• Metabolic acidosis: significant drop in blood pH due to amino acid metabolism.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Sepsis: infection risk linked to central venous catheter use.

When using Numeta G13e, clinicians should assess patient-specific factors and monitor relevant parameters.

• Renal function: adjust infusion rate in patients with impaired kidney function.
• Hepatic function: monitor liver enzymes in patients with liver disease.
• Blood glucose: regularly check glucose levels, especially in diabetic patients.
• Electrolytes: track serum electrolytes to detect imbalances early.
• Compatibility: verify compatibility with other intravenous solutions before co‑administration.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Numeta G13e may interact with other intravenous therapies and medications that affect metabolic balance.

Major Interactions (Avoid)

• High‑dose insulin: may exacerbate hypoglycaemia when combined with amino‑acid infusion.
• Potassium‑rich solutions: can cause severe hyperkalaemia when mixed with Numeta G13e.

Moderate Interactions (Monitor Closely)

• Diuretics: may increase risk of electrolyte disturbances.
• Corticinal corticosteroids: can alter protein metabolism.
• Anticoagulants antico 
• Antifungal 

-